Corcept Therapeutics Inc. (CORT) Stock Price Down 1.1%
Corcept Therapeutics Inc. (NASDAQ:CORT)’s share price traded down 1.1% during mid-day trading on Thursday . The stock traded as low as $5.57 and last traded at $5.63, with a volume of 165,811 shares changing hands. The stock had previously closed at $5.69.
Several research firms have recently weighed in on CORT. FBR & Co reiterated a “buy” rating on shares of Corcept Therapeutics in a research note on Saturday, June 4th. Zacks Investment Research lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th.
The firm’s 50 day moving average is $5.80 and its 200-day moving average is $4.97. The company has a market cap of $621.54 million and a P/E ratio of 624.44.
Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.02. The business had revenue of $19.70 million for the quarter, compared to analyst estimates of $18.36 million. Equities research analysts predict that Corcept Therapeutics Inc. will post $0.05 earnings per share for the current year.
Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.